Allogeneic hematopoietic stem cell transplantation (SCT) is a widely used, cost-intensive procedure. Although pretransplant nonmyeloablative (NMA) or reduced-intensity conditioning regimens appear very promising, prospective studies comparing this approach with the conventional myeloablative (MA) approach in specific hematologic diseases are necessary, especially in patients in whom the conventional approach is not contraindicated. Cost may be an important factor in the decision-making process. We compared the costs of MA and NMA transplants in patients with acute myeloid leukemia (AML). We estimated 1-year resource utilization in 12 consecutive MA patients (median age: 39 years) and in 11 consecutive NMA patients (median age: 58 years) who underwent HLA-identical sibling SCT for AML. Resources care expenses were valued using the average daily rate for personnel costs, supplies, and room costs. Other data were directly collected from the patients' charts. Despite a trend for lower costs in NMA patients during the first 6 months, costs during the 6-12-month period were significantly higher after NMA due to late complications and readmissions (P ¼ 0.03). Finally, mean 1-year costs were not different in MA and NMA patients (P ¼ 0.75). Prospective studies comparing conventional and NMA approaches in homogeneous populations should include economic items. Bone Marrow Transplantation (2005) 36, 649-654. doi:10.1038/sj.bmt.1705109; published online 25 July 2005 Keywords: allogeneic hematopoietic stem cell transplantation; costs; reduced-intensity conditioning regimen Nonmyeloablative (NMA) or reduced intensity conditioning regimens for allogeneic stem cell transplants (SCT) were mainly developed for older patients and those with contraindications to conventional myeloablative (MA) regimens in various hematologic diseases including myeloid 1-9 and lymphoid 10,11 malignancies. In these studies, patients were mostly older than the typical allogeneic SCT recipients and those in the historical control group. [9] [10] [11] [12] Despite this limitation, and the fact that no prospective comparisons between the NMA and MA approaches have been published to date, these studies have shown that NMA transplant may result in an acceptable outcome in patients with no other alternative. One common finding in these series is that the NMA approach reduces the duration of the initial neutropenic phase, 1,2 reduces blood transfusion requirements, 4,5,8 decreases transplant-related mortality, 9,13 and may even be used in an outpatient setting.
Summary:
Allogeneic hematopoietic stem cell transplantation (SCT) is a widely used, cost-intensive procedure. Although pretransplant nonmyeloablative (NMA) or reduced-intensity conditioning regimens appear very promising, prospective studies comparing this approach with the conventional myeloablative (MA) approach in specific hematologic diseases are necessary, especially in patients in whom the conventional approach is not contraindicated. Cost may be an important factor in the decision-making process. We compared the costs of MA and NMA transplants in patients with acute myeloid leukemia (AML). We estimated 1-year resource utilization in 12 consecutive MA patients (median age: 39 years) and in 11 consecutive NMA patients (median age: 58 years) who underwent HLA-identical sibling SCT for AML. Resources care expenses were valued using the average daily rate for personnel costs, supplies, and room costs. Other data were directly collected from the patients' charts. Despite a trend for lower costs in NMA patients during the first 6 months, costs during the 6-12-month period were significantly higher after NMA due to late complications and readmissions (P ¼ 0.03). Finally, mean 1-year costs were not different in MA and NMA patients (P ¼ 0.75). Prospective studies comparing conventional and NMA approaches in homogeneous populations should include economic items. Bone Marrow Transplantation (2005) 36, 649-654. doi:10.1038/sj.bmt.1705109; published online 25 July 2005 Keywords: allogeneic hematopoietic stem cell transplantation; costs; reduced-intensity conditioning regimen Nonmyeloablative (NMA) or reduced intensity conditioning regimens for allogeneic stem cell transplants (SCT) were mainly developed for older patients and those with contraindications to conventional myeloablative (MA) regimens in various hematologic diseases including myeloid [1] [2] [3] [4] [5] [6] [7] [8] [9] and lymphoid 10, 11 malignancies. In these studies, patients were mostly older than the typical allogeneic SCT recipients and those in the historical control group. [9] [10] [11] [12] Despite this limitation, and the fact that no prospective comparisons between the NMA and MA approaches have been published to date, these studies have shown that NMA transplant may result in an acceptable outcome in patients with no other alternative. One common finding in these series is that the NMA approach reduces the duration of the initial neutropenic phase, 1,2 reduces blood transfusion requirements, 4, 5, 8 decreases transplant-related mortality, 9, 13 and may even be used in an outpatient setting.
14 Given these findings, the overall cost of the NMA procedure including drugs, blood products, and hospital resource utilization would be expected to be lower than the conventional treatment using MA conditioning, which usually requires at least 4 weeks of hospitalization compared to 0-3 weeks with the NMA approach. Considering the low transplant-related mortality of the procedure in several series, 4, 5, 8 the time has come to conduct prospective comparative studies between NMA and MA approaches in specific indications. In order to develop such investigational programs, it is necessary to have a cost estimation of the new NMA and the conventional MA approaches. The aim of this study was to compare the costs of NMA transplantation with those incurred by a historical cohort using a conventional MA approach in acute myeloid leukemia (AML) patients over the first year after HLA identical sibling SCT. Both cohorts were treated with the same supportive care regimens.
Patients and methods
In all, 23 patients with AML who underwent MA (n ¼ 12) and NMA (n ¼ 11) conditioning for HLA identical sibling allogeneic SCT in two SCT centers (Henri Mondor and Saint-Louis hospitals) in the Assistance Publique-Hoˆpitaux de Paris group were included in the analysis. The 12 MA patients (median age: 39 years) were all the de novo (n ¼ 11) or secondary (n ¼ 1) AML consecutive patients of the two centers, who were included in a prospective trial (Grefig trial) on the benefit of intravenous immunoglobulins (IVIG). 15 These 12 MA patients underwent transplantation between February 1998 and March 2000. The 11 consecutive patients (median age: 58 years) who received NMA conditioning underwent transplantation for de novo AML (n ¼ 10) or secondary AML following myelodysplastic syndrome (n ¼ 1) between August 2000 and March 2003.
The conditioning regimen in the 12 MA patients consisted either of cyclophosphamide (60 mg/mg on day -5 and -4) and total body irradiation (TBI) (10 Gy singledose or 12 Gy fractionated) (n ¼ 8), or cyclophosphamide (50 mg/kg/day from day -8 to day -5) and busulfan (4 mg/ kg/day from day -9 to day -6) (n ¼ 4). Bone marrow was used in nine patients and peripheral blood stem cells in three patients. Graft-versus-host disease (GvHD) prophylaxis consisted of cyclosporine A and a short course of methotrexate. Prophylaxis for infections was performed according to local practice and included gut decontamination and high-efficiency particulate air filter or laminar air flow room during the neutropenic phase, deleucocyted blood products, weekly CMV screening if donor and/or recipient were CMV seropositive, and pre-emptive treatment of CMV infection with intravenous ganciclovir.
The 11 NMA consecutive patients received fludarabine (30 mg/kg/day from day -4 to day -2) and 2 Gy TBI according to the Seattle' protocol 1 and underwent a peripheral blood SCT. The NMA regimen was proposed to 10 patients because of their age (over 50 years), and to one 44-year-old patient because of anthracyclin-induced cardiac failure. All NMA patients received oral cyclosporine (6 mg/kg/day) until day 84, after which the dose was progressively tapered, and mycophenolate mofetil 15 mg/kg twice daily from day 0 of the transplant to day 27. 4 Donor/ recipient blood chimerism in all NMA recipients was analyzed at days 28, 56, and 84 using a variable number of tandem repeat polymerase chain reactions. Patients with mixed chimerism at day 84 were eligible for donor lymphocyte infusion (DLI), except those with an increase in chimerism of at least 20% between day 56 and day 84 after tapering of cyclosporine. NMA patients were housed in single rooms without HEPA filters. None of them received systemic prophylactic antibiotics or antifungals. Patients were screened for CMV infection and treated according to the same modalities as in the MA transplant patients. Standard criteria were used to diagnose and grade veno-occlusive disease and acute or chronic GvHD in both groups. [16] [17] [18] The severity of infectious events was graded from 1 to 3 according to the previously reported system. 15 GvHD, infectious complications, and relapse were managed according to local routine practice in all patients regardless of the conditioning regimen. Leukemic relapse was managed in both groups, regardless of the type of transplant, according to the general status of the patient, the length of last remission, and the characteristics of the disease.
Evaluation of costs
Costs were computed from the viewpoint of the health care system. We used 2001 prices because 2001 was the median time of the study. We considered that the health care delivery system and the costs of resource utilization to manage SCT patients did not change significantly between 1998 and 2003 in France.
Data collection on resource utilization started on the first day of hospitalization before the conditioning regimen, usually day -8 in MA transplants and day -5 in NMA transplants. Resource utilization included family HLA typing, pretransplantation clinical, biological and radiological evaluation of the recipient and donor, stem cell procurement (bone marrow harvesting or peripheral stem cell mobilization), and conditioning chemotherapy with or without irradiation before transplant. Data were collected over 12 months post transplant or until death, whichever occurred earlier, and included all readmissions in acute care or rehabilitation facilities, outpatient visits, and emergency readmission during the first year after transplant.
All resources were valued using the hospital accounting system in the hematology department of the participating hospitals. Accounting services use an algorithm that allocates a portion of use. For example, the cost of housekeeping is allocated in medical units proportionally to the floor surface, and the cost of department of human resources is allocated proportionally to the number of fulltime equivalents in the medical unit. Medical and nonmedical personnel costs, supplies, and room costs were calculated on the basis of the average daily cost. Overhead costs including maintenance, logistics, administration, billing, and amortization were allocated by the step-down method developed by the hospital administration. Other resources, including TBI costs in both regimens (2 Gy or high-dose TBI), blood bank and donor lymphocyte expenses, expensive investigations (ie CT scans, magnetic resonance imaging, chimerism analysis), and additional pharmacy expenses due to expensive drugs were collected from the patients' charts. The expensive drugs were defined as chemotherapy, cyclosporine, mycophenolate mofetil, antithymocyte globulins, noncellular blood products (ie, IVIG, albumin, plasma), hematopoietic growth factors, and intravenous antiviral, antibacterial, and antifungal drugs. We had already shown in the Grefig trial that there was no benefit of IVIG at any dose compared to placebo in the percentage of patients with one or more infections based on the cumulative incidence of interstitial pneumonia, GvHD, transplant-related mortality, and overall survival. 15 Therefore, we did not include the cost of prophylactic IVIG in the MA population because we considered it would no longer be used for this indication. Overhead costs were allocated using the stepdown method developed by the hospital administration as previously reported. 19 Costs are reported to the nearest hundred euros.
Data analysis
Costs were compared using the Mann-Whitney test, with the SPSS software. A P-value less than 0.05 was considered Cost of minitransplant C Cordonnier et al significant. No adjustment was made for differences in age or comorbidities between the two groups, given the fact that patients receiving the NMA regimen were selected according to these criteria. The survival of the patients in the two arms of the study was not taken into account for these comparisons because all survivors had a minimum follow-up over 12 months and the goal of the study was to compare the cost of transplant during the first year, whatever the clinical result of the transplant. Consequently, the cost of treatment for patients who had a relapse within the 12-month period was also included.
Results
Patient characteristics (Table 1) The MA and the NMA patients were not different for proportions of poor-risk patients (patients transplanted after second complete remission), incidence and severity of acute and chronic GvHD, and incidence of infectious complications with the exception of grade 3 infections, which were significantly higher in NMA patients. Patients in the NMA group were significantly older than those in the MA group (39 years in the MA group (range: 30-48 years) vs 58 years in the NMA group (range: 44-66 years); Po0.001). Two patients in the MA group had venoocclusive disease (one moderate and one severe form). Three of the 12 MA patients developed leukemic relapse during the first year at days 74, 235, and 255, respectively, and five of the 11 NMA patients at days 18, 84, 95, 156, and 167, respectively. No MA patient received DLI. Among the 11 NMA patients, five received DLI, three were for mixed chimerism, and two for leukemic relapse. All the MA patients, and nine of the 11 NMA patients developed infection within 12 months post transplant. At 12-months post transplant, 10 of the 12 MA patients and five of the 11 NMA patients were alive.
Length of hospitalization, use of resources, and total costs from conditioning regimen to 12 months after transplant (Table 2) The duration of the initial admission was significantly shorter for patients in the NMA group. The mean cost of the initial hospitalization in the NMA group was 21.12710.91 KE, representing only one quarter of the total costs during the first year after transplant. However, as the frequency of readmission, mostly for secondary occurrence of GvHD or infectious complications, was higher in the NMA group, the total duration of Cost of minitransplant C Cordonnier et al hospitalization over the first year did not differ significantly between groups. The cost of marrow harvesting was higher than the cost of peripheral blood stem cell harvesting (5.5 KE vs 3 KE), so that the cost of harvest did represent 8.6% of the total cost of the procedure for the MA group, and 5% for the NMA group. There was a trend towards lower costs and less utilization of blood-bank resources within the first 6 months in the NMA group than in the MA group. However, the tendency, although not significant, for blood bank resource utilization was inverse for the last 6 months of the year, so that finally there was no difference between the two groups for transfusion costs over the first year (data not shown). Total costs were not different during the first 6 months, but significantly higher in the NMA group when compared to the MA group during the last 6 months (months 7-12) of the year.
Finally, the mean 1-year total costs did not differ significantly between the two groups (74 900 euros in MA vs 78 700 euros in NMA). The major cost driver (80% of total cost) was length of stay while blood bank and pharmacy expenses represented less than 10% each (data not shown).
Discussion
This study estimates the mean cost of NMA allogeneic HLA identical sibling SCT in patients with AML. It shows that, compared to a historical cohort of younger AML patients treated with the MA approach, the costs did not significantly differ within the first year post-transplant period. To our knowledge, this is the first cost estimation of the NMA transplant approach. Our finding is surprising because the NMA approach is perceived by physicians to be nonaggressive, to have fewer early complications, require less intensive management, fewer transfusions, less expensive drugs, and shorter hospitalization compared to patients receiving conventional MA.
Our study has several strengths. First, data collection for the 12 MA patients was prospective because these patients were part of a larger study to examine the association between costs and patient's pre-transplant status and transplant-related complications. 15, 19 The median costs measured in the 12 MA patients were consistent with the median cost previously reported in the cohort of 85 patients studied in the Grefig trial. 19 Second, we selected all the AML patients consecutively included in the trial in the two centers, avoiding heterogeneity in the underlying disease. Third, the conditioning regimen and management practices for chimerism, immune suppression, and donor DLIs 1 were the same in all NMA patients.
Several studies of allogeneic MA SCT have reported costs ranging between 40 000 and 300 000 USD. [20] [21] [22] [23] [24] [25] This wide variation was at least partly due to different costestimation methods, patient populations, and types of transplant (geno-identical vs unrelated donor, marrow vs peripheral blood SCT). Our group recently showed that the mean cost of geno-identical SCT in France was 76 000 euros with most of the cost due to hospital days. 19 We also showed in the Grefig study 19 a wide range of costs (between 14 000 and 183 000 euros) due to the occurrence of GvHD and repeated infections, each of these episodes adding an average 20-30 000 euros.
Although our results show that both approaches had comparable costs over the first year post-transplant period, several slight differences between MA and NMA transplants should be noted. (1) Costs of NMA transplants varied widely compared to the more homogeneous costs of MA transplants. (2) The time of major expenses differed in the two groups: roughly more than one third of the expenses in the NMA group was spent during the 6-12th month period. This was significantly more than in the MA group. This is consistent with the late onset of complications, especially infections, in NMA transplants, [26] [27] [28] and with the poor tolerance to GvHD among the older patients. It is noteworthy that grade 3 infections were more frequent in NMA patients. (3) Finally, over the full first year post transplantation, there was a trend for higher costs and blood bank resource utilization for NMA transplants, but the difference with MA transplants was not significant.
GVHD and infections are the two factors that account for individual variations in post transplant costs. 19 The other explanation for the difference in the second 6-month period is that more patients relapsed in the NMA group (5/11 vs 3/12) between 18 and 167 days after transplant; Cost of minitransplant C Cordonnier et al however, as four of the five NMA patients and two of the three MA patients who relapsed survived 6 months, more patients were treated for relapse after 6 months in the NMA than in the MA group. Thus, despite the shortened initial admission for patients receiving NMA conditioning, similar costs for both regimens can be expected in the allogeneic SCT setting until there is a reduction in GVHD and infectious complications in patients receiving NMA conditioning. Our study has several limitations. First, it was not a randomized, prospective comparative study. Consequently, we have a significant difference of age in the two cohorts, and this may have clearly influenced the cost of the procedures through the number and severity of complications. However, until prospective comparisons are performed in the same age ranges, this bias is unavoidable since NMA approaches have been mainly reserved for the older patients until now. All previous studies comparing MA and NMA approaches in a specific disease have been retrospective, 9, 12 and none did succeed to match patients on age range. Prospective studies will be of paramount importance in patients who because of age are on the borderline for use of one or the other approach. Previous studies of NMA conditioning have been mainly conducted in patients over 50 or 55 years and thus comparisons may be biased because of the impact of age on the incidence of GvHD and infections. 9, 12, 27, 28 Although transplant-related morbidity among older patients included in NMA programs usually occurs later than in MA transplants, the occurrence of GvHD seems to be similar in both regimens. 12 Data on infectious complications in NMA transplants are conflicting. Shortening the initial neutropenic phase results in reducing the early risk of bacterial and fungal infection. 26, 27 However, it remains uncertain whether the NMA strategy will replace MA regimens in the near future. Second, the rate of post transplant relapse within the first 12 months (3/12 in MA vs 5/11 in NMA patients), and the survival rates at 12 months (10/12 in MA vs 5/11 NMA patients) differed between the two groups. It is unknown whether this higher rate of relapse in the NMA group is due to a higher proportion of patients in first remission at baseline in the MA group, a naturally more resistant disease in the older patients, or to the transplant approach. The question of overall outcome can only be addressed by prospective studies comparing the two approaches. However, our goal was to compare the cost of transplant during the first year from the point of view of the health care system in a planned transplant program anticipating on its budget. From this perspective of 'intention-to-pay', the overall cost is important because patients are cared for until cure or death, regardless of the clinical outcome of the transplant.
Our study highlights that the cost of NMA transplants does not differ from the cost of MA transplants in patients with AML. We should therefore not expect a reduction in transplant costs using NMA conditioning in the near future, unless new developments result in a reduction in GvHD and infectious complications, which are the two main sources of health care expenses. NMA transplants are often complicated by late onset of severe infection, which causes prolonged rehospitalization. While formal cost assessments on larger numbers of patients undergoing NMA are needed, policy makers should not decrease funding of NMA programs in anticipation that costs with these procedures are less than those associated with MA transplants.
